oncomed and celgene partnering to develop and commercialize up to six potential anti-cancer stem cells. shares of oncomed which went public in july and hasn't done much since is certainly making it move today, up 106% on oncomed at $28.96. under the terms of the deal oncomed will receive $177.25 million up front from celgene including a $22.25 million equity investment. shares of celgene have been trading on the downside in an otherwise down market but down about 1.3% at 160.26. barbara ryan, managing director with fti consulting joins us to talk about the deal. good to see you again. >> nice to see you, sue. thanks for having me. >> you know, celgene has been aggressive in pursuing different pipelines if you will. this seems to be another kind of innovative deal on their part? >> absolutely. i think there's two important things to note. you're right, this following deals with epigene and blue bird that celgene has done as well as agio, all companies that went company for break through potentially early but break through therapies. the second point is we've had nearly 40 companies in

they had a pullback, it's partnered with celgene.ur thoughts. >> what stock did you mention? you mentioned apple. i would buy apple, what was the sponsored by t.d. ameritrade. >>> what's happening with chart industries? here's a company we've liked for a long time. major maker of cryogenic equipment and as well as lng stores and engine tanks, plus it is an industrial gas division where they make liquid oxygen therapy systems. vince sells for 37 times next year's earnings estimates with a 40% long-term growth rate. kors sells fo 2tis xt cf1 o >> unlike, vince holdings has overship apple and it has the astounding 70% of the company. >> do you lock up and all of that said i do think vince is tradable and let me tell you why. the post-ipo quiet period ends and that means all of the bankers who wanted to rewrite the post-ipo quiet period ends and that means all of the bankers who wanted to rewrite the deal want coverage on the stock. you get positive research and i wouldn't be surprised at all if vince doesn't rally with that. why don't t

celgene is seeking approval for pancreatic cancer.e know how difficult that one is, and metastatic melanoma, as well. the third leg is one no one's talking about, which is an immunology and inflammation drug that's still in development, which i think could be a breakout drug for rheumatoid arthritis, where there really is nothing good out there. plus celgene sells for 23% growth rate and it's ridiculous. if you look at 2013 and 2016. gilead asked for time in the premiere maker of hiv drugs which transformed it from a death sentence to an albeit manageable life long condition. it's getting its hands on the hepatitis c drug candidates that are miles ahead of the current standard of care, with much higher rates of actually curing the disease. gilead just got fda approval for the main hep-c drug earlier this month, and i think it's going to be huge. don't get me wrong. this company has a terrific pipeline with cancer treatments that are definitely not in the stock price. people are only looking at the hiv and the hep-c. biogen idec's brea

they had a pullback, it's partnered with celgene.e your thoughts. >> what stock did you mention? you mentioned apple. i would buy apple, what was the other stock you mentioned? celgene, i would buy both of those before i would buy epizyme and it is the number one football team in the country. and that, ladies and gentlemen, is the conclusion of the lightning round! >>> the lightning round is sponsored by t.d. ameritrade. ♪ like, really big... then expanded? ♪ or their new product tanked? ♪ or not? what if they embrace new technology instead? ♪ imagine a company's future with the future of trading. company profile. a research tool on thinkorswim. from td ameritrade. ♪ [ male announcer ] 1.21 gigawatts. today, that's easy. ge is revolutionizing power. supercharging turbines with advanced hardware and innovative software. using data predictively to help power entire cities. so the turbines of today... will power us all... into the future. ♪ people find out state farm does car loans as well as they do insurance, our bank is through. good

and they are celgene, gilead, biogen and regeneron.ll four of these stocks have had axe mazing runs this year. i'm well aware of that and i've been recommending them aggressively for a long time on the show. i think they're fantastic. celgene is basically a three-legged school of innovate of drugs. first one is made of the multiple myeloma franchise, which is a derivative of a poison. a poisonous drug. this drug has a lot of room to grow, particularly in europe. the second leg is apraksame. this is a potential blockbuster oncology drug approved for breast cancer and nonsmall cell lung cancer it is seeking approval for pancreatic cancer. we know how difficult that one is and metastatic melanoma, as well. the third leg is one no one's talking about which is an immunology and inflammation drug that's still in development which i think could be a breakout drug for rheumatoid arthritis, where there really is nothing good out there, plus celgene sell, 23% growth rate and it's ridiculous. if you look at 20-13 and 2016. gilead asked for time i

. >> i remain a buy of biomarin as i do celgene, gilead, regeneron, steve? >> caller: boo-yah.stock is fedex, fdx, what do you think about it? >> i prefer u.p.s. to fedex. but fedex is real good. tom in connecticut, tom? >> caller: insurance international group holdings, eigi. >> do not know it. do not know endurance. do not know it. let's go to john in new jersey, john? >> caller: mr. jim cramer. >> what's happening? hit me. >> caller: dgo -- >> no, no, no, no -- >> sell, sell, sell -- >> you want a gold stock, you've got to go to rand gold. i prefer the gld, understand that gold is not going up right now, but we can stay long it as a hedge. it's a currency. jay in new york, jay? >> caller: manhattan boo-yah. >> nice. brooklyn boo-yah back at you. what's up? >> caller: guidance. i need some guidance on a stock you seem to like, sirius xm satellite. >> analysts were lukewarm on that last quarter. it wasn't that big a miss. i think you should buy it. i like sirius. and i particularly like -- i like that guys running that company. i think they're very good. you want to be long si

taking a look at celgene.res are rising along with other bio surgical companies are news they may have found a treatment for leukemia that does not include chemotherapy. they presented the research at a medical conference in new orleans this weekend. more on this in just 30 minutes. ♪ >> this is the early edition of bloomberg "west." i'm emily chang. bloomberg top headlines. riot police out in full force in ukraine's capital. raided the headquarters of an opposition party and toward down barricades put up i.e. anti-government protesters. they want the president to resign after he rejected a trade he'll. and american airlines have officially completed their merger, creating the world's largest airline out called american airlines route. over the coming months, the companies will work on integrating networks, frequent flyer programs, reservation systems and more. -- a gold medal won by jesse erwin has sold for more than $1.4 million at auction. that is a record highs for a piece of memorabilia. educationallans a

we like gilead, right, we like celgene and regeneron. we are not daeviateing from those for. siad in connecticut. >> caller: i want your impact which will come from results of an 81 date of clinical trials of bb 27, your thoughts and let us know what you think about that. >> i know it spiked on that. that's not good enough. anybody can see that from the chart. i have learned my lesson, when you opine without a recent analysis on a biocap under 3 billion. we have to do a much more homework driven analysis of puma. all week, we helped your stocking stuffs for gifts that keep on giving. look no further, google, ciena. oh, apple, cat, tjx, jnj not all red hot. stocks you can still buy. remember, stocks are a great gift for kids. we wish you a very, merry christmas. it is time, it is time for the lightning round. we tell you whether to buy, buy, buy, or sell, sell, sell. you hear this sound and the lightning round is over. are you ready, ski-daddy? we want to start with dan in ohio. dan! >> caller: hey, jim. i am looking at an energy stock at an 8-year low. >> edid an analysis of

that's celgene. what you have to do is you plot how your stocks have done against a market in good times and bad, when there's growth and no growth. that's what i do. i've looked back using charts, 1989 and 1991. 1996, 1998, 2000, 2002 and see how they've done. you've got to do that history if you really want to feel confident that you have a secular grower whose numbers don't get cut, versus a cyclical grower whose numbers get cut. a whole chapter on that in "get rich carefully." sonny in illinois. sonny! >> jim cramer, a big chicago windy city boo-yah to you. >> sweet. >> hey, jim, i'm always taking your advice. longtime fan. enjoy your show and your books. >> thank you. >> i have a general question for you. so i'm always taking your advice and reading up on the companies, going in and listening in on the quarterly conference calls. a company reports solid numbers and fundamentals, what is your definition? >> i've always used 5% to 7%. something lee cooperman when he was the research director at go

drop for celgene's. >> it's from 173-ish down to 160. >> i think it's fun. we have seen telesells before. i love the name. >> pop for herbal life up 1%. >> it was up 10 yesterday. so it's a total of 11 over two days. it's a classic short squeeze. there is an upside bias in its name. >> j.c. penney down 3%. >> weekly retail sales came in weaker than expected. jc penney, i'm not sure how impacted they are. $8 seems to be a bit of a for this day. >> k.b. holmes down 1%. tim. >> on a day when you have an index print. you see a lot of pressure, a big downgrade, ultimately, people will be looking at their 4th quarter numbers out thursday and oracle is expected to be down 5%. >> and we got a drop for botox t. reigning cosmetic cure all is facing a celebrity backlash, after ten years of eraseing a-list wrinkments, hollywood a-star listers are turning the other cheek. nicole kidman saying i can now feel my face. gwyneth paltrow says she begged it off because she'd look like joan rivers. >> it's close. not really. not really. >> the point was being fa facetous. >> spe

netflix, best buy, delta airlines, celgene.der put it to me, imagine this, if you missed out on this rally of 2013, are you willing to pay top dollar for these stocks, especially the fact that stocks are trading at price valuations. >> is it really top dollar, though, if we were just to say priced to earnings ratio are where they were, and i will say this, but people might pay more for every dollar of earnings. adam parker at morgan stanley, who a couple years ago was the most bearish strategist on wall street, is the most raging bull. the reason why, he says multiple expansion can happen. people will want to pay more for every dollar of earnings because of major thing. belief the fed can distinguish between tapering, which is just withdrawing some stimulus, versus actually raising interest rates. if people can get their arms around that, that's a good sign. also a lack of credible bear case against any kind of an earnings growth scenario. there isn't one right now. companies are still trying to boost their profits and they can

biotechs, celgene, gilead itself is up almost 100%. why will it still work? >> great reasons. up. >> i'm listening. >> this will give you movement and value. i have 3.66 for next year's numbers, and then six bucks, and then eight bucks. they have 15 drugs now in phase two. they've got basically four or five drugs that are in approval in phase three, applying here, applying there. but they've already got earnings. this stock is going to double over the next year, year and a half. >> wow. >> 23 buy ratings, zero sells, up 85% this year. why -- how does the market look -- >> this guy is a bandwagon kind of a guy, right? [ laughter ] >> -- the motivation focusing on where stocks have come from? >> where it is right now, 20 times cash flow. >> -- market in '09, the point is -- >> if i had a dime if you said, it's not where they come from, it's where they go. >> and that's absolutely true. i'd be are rach man. >> thank you. thank you for gratifying -- >> you should get that -- here, 23 buys. sometimes the crowd can be right. this is one of the times. >> all right. >> here's one of t

components within the biotech industry that have done well, as the sector has done well, we know about celgene and gilead and biogen and amgen, and lexion. which names will lead? >> i like gilead a lot. i was talking to a by bio-pharma, and he believes the hep-c market is laying out there for ldig to take advantage of. they got positive news out of that recently. i think that continues to work for them, judge. and i wouldn't bet against carl icahn or anybody else in biogenetic, bgib, and i know daummy made a great pick. >> how about, mike murphy, internet retail up 41% year to date, and the gains have really rolled into the fourth quarterment you have internet retail up 21%, the names within the space. we know amazon. expedia, netflix, the performance speaks for itself, best performing s&p stock year-to-date, tripadvisor. >> the whole space works, so if you're in amazon, trading near $400, there's nothing out there telling you to sell it, take some off the table. that continues to work. however, if you're looking to get a new position, i would not be advising anyone to go out there and say, he

earlier in the week, refer, celgene made a deal to jointly develop six anti-cancer drugs, kelly. >>> coming up next, for those of you unnerved about reports of a consumer spending slowdown on black friday, mike holebertz says there's a silver lining for investors. he'll join us to explain what that means. >>> also ahead, rick santelli joins us from the cme in chicago. what are you working on, rick? >> we're going to work on a comment you made. you said, i wonder if the retreat in stock is they're digging into the gdp numbers. i don't think so. but peter and i will dig into them, nonetheless. bottom of the hour, folks. [man]ask me... [announcer] ...every wish for a bed that could feel perfect under every part of your body... [man]ask me about our tempur-pedic. [announcer] they're sleeping on the newest tempur-pedic bed... the new tempur choice... [man]two remotes. [announcer] firmness settings for the head,legs,and back... these real owners get that famous tempur-pedic comfort how they like it. [woman]ask me about the lumbar button. [man]lumbar button [woman]lumbar [announcer] tem

. >> up on celgene. >> go buy celgene deep on money calls. >> pinnacle. >> they had a couple great quartersp the balance sheet, gives them opportunity to buy a lot more companies. >> you are all business today, jim. what's coming up tonight? >> a little less than business. one of the things we're looking into is the smokeless tobacco, njoy, i want to know more about it. and ski apparel, morris goldfarb is blowing out the numbers, i think sports apparel, giii, undera underarmour, nike. this is not rg3 where the controversy has gotten so bad. >> of course you must be happy with the way the bears acquitted themselves in the cold last night. philly leads -- >> we have to come to philadelphia to play chicago and then we play dallas. the dallas game is a silver linings play book moment. go watch the movie. it will be repeated in real life. i don't get the girl. just a little heads up. i've seen the movie. >> simon is here with what's coming up at 10:00. >> good morning, carl. we'll look at what gm will look like under its new ceo mary bar barra. the volcker rule is through. we'll have the latest.

look to some of the larger cap biotechs that have growth but are more defensively positioned like celgenealked about those on "mad money." if you're going defensive, go biotech. i wouldn't be a buyer of dividends. >> quick point. cancer is becoming a chronic condition. it's starting to avoid the terminal condition. right into the play of biotech sector, i totally agree. >> very good. see you both. thank you for joining us today. >>> we'll take a break in a moment. first word of insider trading scandal involving microsoft. dominic chu has been working on this story. what did you find out? what's going on? >> sure, bill. what we have is the s.e.c. charging, alleging that a microsoft senior manager, brian jorgenson, allegedly was involved in insider trading. the s.e.c. alleges that brian jorgenson who worked in microsoft's corporate finance and investments division tipped off a friend, shawn stowky, in advance of material nonpublic information. the s.e.c. cites three separate instances of this alleged insider trading that netted approximately $400,000 in these profits. so as you go through w

celgene bought oncomed. came off lows after it said walmart.com had its best sales day ever on cyber monday. disney, one of the worst performers on the dow. b. riley downgraded from neutral to buy. it's up 40% so far this year. sectorwise, airline stocks are falling. this as oil prices hit a one-month high overall. can you see there, some of the at least downdraft for some of those shares on the airline sector. kel y bill, back over to you guys. >> for amr. thank you, dom. >>> our next guest is here with an exclusive look at what he thinks will move the economy in 2014. >> anthony in arizona and bob pisani. you expect the economy to grow 2.5% in the next year. is it improvement enough to warrant fed tapering? we'll cut to the chase. >> there's no doubt the federal reserve is anxious to start tapering. that will occur over the next couple of months. but remember the tapering will be incremental. they told us they'll continue to keep short-term interest rates at low levels so it won't be all that bad. >> antho

. >> celgene is a buy here. >> liked asian ear, though. >> well, pell low. this is a.le this is a very exciting thing. >> goldman conviction buy on dollar -- >> you know what's selling more? i hate to say this, the cigarettes. >> a lot of people thought the optical business might not be well for teleco. look out. the stock will be up more than this. >> you brought a lot of ideas to "mad" this week. what's on tonight? my first michael power washed myself. they make a lot ennui have the breaks in strategy. but next motors. >> steered name. we'll see you tonight. good luck against detroit this weekend. >> i'm so nervous, carl. and i've got fantasy, too, the playoffs. great show of. >> and we're on winter storm watch and pop parties. ho dope heads are celebrating the legalization of marijuana. ading. i love having a free checked bag with my united mileageplus explorer card. i've saved $75 in checked bag fees. [ delavane ] priority boarding is really important to us. you can just get on the plane and relax. [ julian ] having a card that doesn't charge you foreign transactio

biotech, also a major outperformer, gilead sciences, celgene, and deckers, the parent company of uggss and r.r. donnelly making the 100% club. eight of them are up 200% in the past year. momentum up. netflix, micron technology, tesla, you can't count out brick-and-mortar retail. best buy up more than 240% in the past year. as for whether we are going to see more gains from these stocks, mixed picture. half of the names on our list actually had already hit analyst price targets when it comes to what their stock price could be. if the analysts are right, perhaps limited up-side. we did find a few exceptions, delta airlines being one of them. analysts predict they could see a 20% pop over the next 12 months if they hit the average price targets. tune in to the halftime report. at halftime, we are going to be talking about the 400% club. five names that have hit more than 400% gains this year alone. back to you. >> thank you so much, sheila. let's turn dan on that note. some of the momentum fliers that have doubled, tripled, quadrupled, are those easy shorts? >> for a stock like a best bu

. >> and when celgene makes a deal with you, your stock flies. >> what's tonight?arter. >> this is one of the most controversial companies. if you're going to liquify natural gas, you need their tanks, you need their infrastructure. but they're a huge player in china and they lowered the boom last time they were on. this has been we call them investor business daily stock, one of those momentum plays. i liked it from the 20s and 30s. it got really overheated, they slashed their guidance, the stock got hammered and morgan stanley upgraded it. is this the beginning of another cycle? i don't know. i have to find out myself because i was let down myself, the quarter was not good. >> we're looking at potentially our third day down on the dow. we haven't done that since late september. what do you tell people who sat out the year? >> i'm looking for those buyers. just watch bonds. if bonds can stay -- the 10-year can stay at 2.75, then you have to come in and buy. if it goes to 2.6, buy aggressively. otherwise you'll get a better opportunity. watch this. this is everythi